Talphera (Talphera) ROCE % : -101.43% (As of Dec. 2023)

View and export this data going back to 2011. Start your Free Trial

What is Talphera ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Talphera's annualized ROCE % for the quarter that ended in Dec. 2023 was -101.43%.

Talphera ROCE % Historical Data

The historical data trend for Talphera's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Talphera ROCE % Chart

Talphera Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-55.61

-58.65

-60.72

129.44

-40.94

Talphera Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
ROCE %	Get a 7-Day Free Trial															-69.29	2.90	-104.67	-34.13	-101.43

Talphera ROCE % Calculation

Talphera's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-10.153	/	( ( (47.487 - 13.77)	+	(20.395 - 4.512) )	/ 2 )
	=	-10.153	/	( (33.717	+	15.883)	/ 2 )
	=	-10.153	/	24.8
	=	-40.94 %

Talphera's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	-18.04	/	( ( (23.261 - 3.574)	+	(20.395 - 4.512) )	/ 2 )
	=	-18.04	/	( ( 19.687	+	15.883 )	/ 2 )
	=	-18.04	/	17.785
	=	-101.43 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

Talphera (NAS:TLPH) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Talphera ROCE % Related Terms

Thank you for viewing the detailed overview of Talphera's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Talphera (Talphera) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Talphera Inc (NAS:TLPH) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

R5XA:Germany

Address

25821 Industrial Boulevard, Suite 400, Hayward, CA, USA, 94545

Website

https://www.acelrx.com

Talphera Inc. is a pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings. Its product portfolio includes Niyad that is a lyophilized formulation of nafamostat. It is also developing two pre-filled syringes, a pre-filled ephedrine syringe, and PFS-02, a pre-filled phenylephrine syringe.

Executives

Vincent J. Angotti	director, officer: Chief Executive Officer	C/O ACELRX PHARMACEUTICALS, INC., 351 GALVESTON DRIVE, REDWOOD CITY CA 94063
Pamela P Palmer	director, officer: Chief Medical Officer	C/O ACELRX PHARMACEUTICALS, INC., 351 GALVESTON DRIVE, REDWOOD CITY CA 94063
Jill Marie Broadfoot	director	3545 JOHN HOPKINS COURT, SUITE 250, SAN DIEGO CA 92121
Marina Bozilenko	director	C/O ACELRX PHARMACEUTICALS, INC., 351 GALVESTON DRIVE, REDWOOD CITY CA 94063
Adrian Adams	director	C/O AUXILIUM PHARMACEUTICALS, INC., 640 LEE ROAD, CHESTERBROOK PA 19355
Mark G Edwards	director	ALLOS THERAPEUTICS, INC., 11080 CIRCLEPOINT ROAD, SUITE 200, WESTMINSTER CO 80020
Raffi Asadorian	officer: Chief Financial Officer	C/O ACELRX PHARMACEUTICALS, INC., 351 GALVESTON DRIVE, REDWOOD CITY CA 94063
Lawrence G Hamel	officer: Chief Development Officer	C/O ACELRX PHARMACEUTICALS INC., 351 GALVESTON DRIVE, REDWOOD CITY CA 94063
Badri N Dasu	officer: Chief Engineering Officer	C/O ACELRX PHARMACEUTICALS, INC., 351 GALVESTON DRIVE, REDWOOD CITY CA 94063
Mark A Wan	director, 10 percent owner	C/O THREE ARCH PARTNERS, 3200 ALPINE RD, PORTOLA VALLEY CA 94028
Three Arch Associates Iii Lp	10 percent owner	C/O THREE ARCH PARTNERS, 3200 ALPINE ROAD, PORTOLA VALLEY CA 94028
Wilfred E Jaeger	10 percent owner	C/O THREE ARCH PARTNERS, 3200 ALPINE RD, PORTOLA VALLEY CA 94028
Three Arch Partners Iii Lp	10 percent owner
Three Arch Partners Iv Lp	10 percent owner
Three Arch Associates Iv Lp	10 percent owner	3200 ALPINE ROAD, PORTOLA VALLEY CA 94028